This is what I found on NPR.ORG:

A closely watched but controversial treatment for peanut allergies took a big step closer to becoming widely available.

On Friday, an advisory committee of the U.S. Food and Drug Administration voted 7-2 to approve Palforzia, a standardized peanut powder product, to help reduce allergic reactions to peanuts for patients ages 4 to 17 as part of oral immunotherapy protocol. The treatment was developed by pharmaceutical company Aimmune Therapeutics.

The committee’s vote could be a landmark in addressing peanut allergies, which currently have no FDA-approved treatment, leaving allergic people little choice but to avoid peanuts. The FDA usually follows the recommendations of its advisory committees. A final decision is expected early next year.

Concerns were raised about the treatment leading to more allergic reactions, in some cases.

Information provided by NPR.ORG.

Leave your comments below.